What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?
[Display omitted]
Gespeichert in:
Veröffentlicht in: | JACC. Cardiovascular interventions 2024-02, Vol.17 (3), p.419-421 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 421 |
---|---|
container_issue | 3 |
container_start_page | 419 |
container_title | JACC. Cardiovascular interventions |
container_volume | 17 |
creator | ten Berg, Jurriën M. Overduin, Daniël C. van Ginkel, Dirk-Jan |
description | [Display omitted] |
doi_str_mv | 10.1016/j.jcin.2023.12.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2927212141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1936879823016606</els_id><sourcerecordid>2927212141</sourcerecordid><originalsourceid>FETCH-LOGICAL-e264t-d39c8840e0283f92c31d200534e283455ecd079e985385705d858e4fc6de6d4e3</originalsourceid><addsrcrecordid>eNptkU1Lw0AQhhdRbK3-AQ-yRy-J-5FNNiJIrF_FQkFqPa5xd1I35KNmE8F_b2LrzdMMw8PwzjwInVLiU0LDi9zPta18Rhj3KfMJC_bQmMoo9KKQiP2-j3noySiWI3TkXE5ISOKIHaIRl1wIFpExenv9SFu8aNICJ1VrdZ2uuyKtWjxz-AZci5OshQYvk9XzJV7ZNi1thZ8GNl3XlXWtw3WDb20D-r817voYHWRp4eBkVyfo5f5uOX305ouH2TSZe8DCoPUMj7WUAQHCJM9ipjk1jBDBA-gHgRCgDYliiKXgUkREGCkkBJkODYQmAD5B59u9m6b-7PrkqrROQ9GngLpzisUsYpTRgPbo2Q7t3kswatPYMm2-1d9XeuBqC0Af-MtCo5y2UGkwv3cqU1tFiRokqFwNEtQgQVGmegn8B-sLd70</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2927212141</pqid></control><display><type>article</type><title>What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>ten Berg, Jurriën M. ; Overduin, Daniël C. ; van Ginkel, Dirk-Jan</creator><creatorcontrib>ten Berg, Jurriën M. ; Overduin, Daniël C. ; van Ginkel, Dirk-Jan</creatorcontrib><description>[Display omitted]</description><identifier>ISSN: 1936-8798</identifier><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2023.12.024</identifier><identifier>PMID: 38355270</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Anticoagulants - adverse effects ; antithrombotic treatment ; Aortic Valve - diagnostic imaging ; Aortic Valve - surgery ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - drug therapy ; DOAC ; Fibrinolytic Agents - therapeutic use ; Humans ; oral anticoagulation ; transcatheter aortic valve replacement ; Transcatheter Aortic Valve Replacement - adverse effects ; Treatment Outcome ; Vitamin K ; VKA</subject><ispartof>JACC. Cardiovascular interventions, 2024-02, Vol.17 (3), p.419-421</ispartof><rights>2024 American College of Cardiology Foundation</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcin.2023.12.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38355270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ten Berg, Jurriën M.</creatorcontrib><creatorcontrib>Overduin, Daniël C.</creatorcontrib><creatorcontrib>van Ginkel, Dirk-Jan</creatorcontrib><title>What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>[Display omitted]</description><subject>Administration, Oral</subject><subject>Anticoagulants - adverse effects</subject><subject>antithrombotic treatment</subject><subject>Aortic Valve - diagnostic imaging</subject><subject>Aortic Valve - surgery</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>DOAC</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>oral anticoagulation</subject><subject>transcatheter aortic valve replacement</subject><subject>Transcatheter Aortic Valve Replacement - adverse effects</subject><subject>Treatment Outcome</subject><subject>Vitamin K</subject><subject>VKA</subject><issn>1936-8798</issn><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1Lw0AQhhdRbK3-AQ-yRy-J-5FNNiJIrF_FQkFqPa5xd1I35KNmE8F_b2LrzdMMw8PwzjwInVLiU0LDi9zPta18Rhj3KfMJC_bQmMoo9KKQiP2-j3noySiWI3TkXE5ISOKIHaIRl1wIFpExenv9SFu8aNICJ1VrdZ2uuyKtWjxz-AZci5OshQYvk9XzJV7ZNi1thZ8GNl3XlXWtw3WDb20D-r817voYHWRp4eBkVyfo5f5uOX305ouH2TSZe8DCoPUMj7WUAQHCJM9ipjk1jBDBA-gHgRCgDYliiKXgUkREGCkkBJkODYQmAD5B59u9m6b-7PrkqrROQ9GngLpzisUsYpTRgPbo2Q7t3kswatPYMm2-1d9XeuBqC0Af-MtCo5y2UGkwv3cqU1tFiRokqFwNEtQgQVGmegn8B-sLd70</recordid><startdate>20240212</startdate><enddate>20240212</enddate><creator>ten Berg, Jurriën M.</creator><creator>Overduin, Daniël C.</creator><creator>van Ginkel, Dirk-Jan</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20240212</creationdate><title>What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?</title><author>ten Berg, Jurriën M. ; Overduin, Daniël C. ; van Ginkel, Dirk-Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e264t-d39c8840e0283f92c31d200534e283455ecd079e985385705d858e4fc6de6d4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Administration, Oral</topic><topic>Anticoagulants - adverse effects</topic><topic>antithrombotic treatment</topic><topic>Aortic Valve - diagnostic imaging</topic><topic>Aortic Valve - surgery</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>DOAC</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>oral anticoagulation</topic><topic>transcatheter aortic valve replacement</topic><topic>Transcatheter Aortic Valve Replacement - adverse effects</topic><topic>Treatment Outcome</topic><topic>Vitamin K</topic><topic>VKA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ten Berg, Jurriën M.</creatorcontrib><creatorcontrib>Overduin, Daniël C.</creatorcontrib><creatorcontrib>van Ginkel, Dirk-Jan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ten Berg, Jurriën M.</au><au>Overduin, Daniël C.</au><au>van Ginkel, Dirk-Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2024-02-12</date><risdate>2024</risdate><volume>17</volume><issue>3</issue><spage>419</spage><epage>421</epage><pages>419-421</pages><issn>1936-8798</issn><eissn>1876-7605</eissn><abstract>[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38355270</pmid><doi>10.1016/j.jcin.2023.12.024</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1936-8798 |
ispartof | JACC. Cardiovascular interventions, 2024-02, Vol.17 (3), p.419-421 |
issn | 1936-8798 1876-7605 |
language | eng |
recordid | cdi_proquest_miscellaneous_2927212141 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Administration, Oral Anticoagulants - adverse effects antithrombotic treatment Aortic Valve - diagnostic imaging Aortic Valve - surgery Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy DOAC Fibrinolytic Agents - therapeutic use Humans oral anticoagulation transcatheter aortic valve replacement Transcatheter Aortic Valve Replacement - adverse effects Treatment Outcome Vitamin K VKA |
title | What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T07%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20Oral%20Anticoagulant%20Is%20Best%20After%20TAVR:%20Vitamin%20K%20Antagonists%20or%20Direct%20Oral%20Anticoagulants?&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=ten%20Berg,%20Jurri%C3%ABn%20M.&rft.date=2024-02-12&rft.volume=17&rft.issue=3&rft.spage=419&rft.epage=421&rft.pages=419-421&rft.issn=1936-8798&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2023.12.024&rft_dat=%3Cproquest_pubme%3E2927212141%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2927212141&rft_id=info:pmid/38355270&rft_els_id=S1936879823016606&rfr_iscdi=true |